Drostanolone Propionate is an injectable steroid derived from dihydrotestosterone. Here, the modification of the structure of dihydrotestosterone and the 2-methyl group can enhance its anabolic function, making drostanolone propionate more effective than testosterone in promoting muscle growth. More effective. drostanolone propionate is described as a “powerful anabolic steroid and anti-estrogen drug” in some instructions, and it does have both steroid and anti-estrogenic properties. However, its anabolic properties are considered moderate, especially when other agents are used. This drug is most commonly used by bodybuilders who are dieting or athletes in speed training. It can increase muscle stiffness, increase the amount of lean meat and muscle strength, reduce body fat levels, and reduce side effects.
Drostanolone propionate first came out in 1959, in addition to other famous steroids “Anadrol”. But drostanolone propionate was not used as a prescription medicine until about ten years after its introduction. Eli Lilly and Xingtai Ke Pharmaceutical Co., Ltd. have reached an agreement under which the two parties share a certain amount of research and development costs in exchange for the right to market research results. Therefore, in the US market, Eli Lilly’s products are sold under the name drostanolone propionate, while other markets are owned by Xingtai Ke.
The US Food and Drug Administration approved drostanolone propionate for the treatment of postmenopausal women with advanced breast cancer, which is also the FDA’s clinical guidance for drostanolone propionate in the international market. Relevant research literature also reminded doctors and female patients that the virilization reaction of patients who took drostanolone propionate at the same dose was less than that of testosterone propionate. So drostanolone propionate is a more assured substitute for testosterone injections.
In the 1970s and 1980s, Drostanolone propionate enjoyed a high reputation among athletes. But the good times didn’t last long, and manufacturers began to stop selling the drug as an agent. It may be due to the emergence of more effective treatments for breast cancer, and the slow reduction of prescription steroids at this stage. But drostanolone propionate is still on sale in the United States, and there are no legal restrictions on the market, but it seems unlikely that it will appear again as a prescription drug product.
Post time: Oct-15-2020